BioMarin ups the ante for pivotal haemophilia gene therapy trial – PMLiVE
PMLiVE |
BioMarin ups the ante for pivotal haemophilia gene therapy trial
PMLiVE BioMarin is dramatically expanding the size of a phase III trial of its gene therapy for haemophilia A, after reporting long-term efficacy data from another study which showed clear evidence of efficacy two years after dosing. Increasing the size of … |
